GET DAILY SIGNALSLifeVantage (LFVN): Analyst Targets Point to +35–40% Upside Potential
Key Takeaways
- The central price target of $7.50 is the arithmetic mean of two verified analyst price targets for LifeVantage Corporation (LFVN), a Utah-based health-and-wellness company.
- With shares trading near $5.30–$5.50, reaching $7.50 would require a gain of roughly 35–40% — a substantial move from current levels.
- Analyst coverage is thin and divergent: the two current targets span $6.00 to $9.00, reflecting very different views on the company's turnaround.
- Supportive factors include a new chief executive, a $60 million share-buyback authorization, a dividend yield near 4%, and a debt-free balance sheet.
- The biggest risks are declining revenue, falling consultant counts, intensifying GLP-1 product competition, and the withdrawal of fiscal 2027 guidance.
- You can explore Major News, Today's Price Move, Forecast, and Earnings pages for deeper coverage of this ticker.
- For automated market monitoring, explore Trending AI Robots to see how AI-driven tools track changing market conditions.
Analyst Price Targets and Consensus View
LifeVantage remains a thinly covered micro-cap, with just two current analyst price targets. Lake Street analyst Ryan Meyers maintains a Hold rating and a $6.00 target, which he raised from $5.00 in late August 2026; he described the fiscal fourth quarter as mixed and expects shares to stay range-bound until revenue stabilizes. Freedom Broker’s Ilya Zubkov holds a Buy rating with a $9.00 target, noting that current prices appear overly pessimistic and highlighting the buyback program, dividend, and ongoing profitability.
The average of these two targets comes to $7.50, with the range stretching from $6.00 to $9.00. That 50% spread between the high and low illustrates real differences of opinion on whether the company’s reset will deliver renewed growth. With only two analysts contributing, this average serves as a directional reference rather than a firm consensus.
Current Market Position and Path Toward the Target
Shares of LFVN have moved within a 52-week range of roughly $3.90 to $11.71 and recently traded near $5.30–$5.50. Closing the gap to $7.50 would mean an advance of about 35–40%, a meaningful step for a company whose revenue is still contracting.
Fundamentals add complexity. Fiscal 2026 revenue declined about 20% year over year to roughly $182.6 million, missing the company’s own $185–$200 million guidance as MindBody GLP-1 sales faced difficult comparisons and consumer demand softened more broadly. The consultant base fell to about 76,000 from roughly 100,000 a year earlier. New CEO Terrence Moorehead, who took over from retiring chief executive Steve Fife, has emphasized brand building, product relevance, and efficiency but withdrew formal fiscal 2027 guidance while the strategy review continues.
What Could Support a Move Toward the Target
Several elements could help drive a re-rating. The company carries no debt, maintains gross margins near 79%, and remains modestly profitable while paying a dividend that yields roughly 4%. A $60 million repurchase authorization extending through late 2027 offers potential support for share demand, and management’s focus on deepening penetration in existing markets rather than costly expansion could aid margins. A credible turnaround under new leadership, with clearer strategic targets and stabilized revenue, would be the most direct catalyst for higher analyst targets. The international business and recurring autoship orders, which account for a large portion of sales, also provide some revenue visibility.
What Could Prevent the Target From Being Reached
The main hurdles remain revenue contraction, consultant attrition, and strong competition in the GLP-1 weight-management space. Recent quarters have shown softening demand across the broader product portfolio, not only in GLP-1 items, with average order sizes declining. The lack of formal fiscal 2027 guidance increases uncertainty, and execution risk during the CEO transition is notable. Valuation could face further pressure if growth continues to disappoint; with limited analyst coverage and a reduce-leaning tilt in some third-party aggregations, sentiment stays fragile.
Technical Levels and Market Structure
The $7.50 target lies well above the recent trading range but below the 52-week high near $11.71, a reminder that the stock has previously commanded higher valuations. The 52-week low near $3.90 marks a key support zone, while the $6.00 area, close to Lake Street’s target and prior analyst reset levels, could serve as initial resistance on any recovery. Shares have also traded below their 200-day moving average, indicating that the longer-term trend remains under pressure.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month horizon, and both current targets align with that timeframe. I’m watching quarterly earnings closely for signs that revenue declines are stabilizing, any reintroduction of guidance or quantified strategy from the new CEO, and potential revisions to analyst targets. Updates on consultant and active-customer counts, GLP-1 competitive dynamics, buyback activity, and consumer-spending trends will be the clearest signals on whether the $7.50 level becomes more attainable.
Using Tickeron Tools in Research
I also checked this using Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts that limited analyst coverage might overlook. These signals help identify emerging trends and changes in market dynamics for names like LFVN.
Promo Section
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful way to track momentum across thousands of stocks and ETFs. The tool generates Buy, Sell, or Hold signals based on technical behavior and AI analysis, which can be especially helpful for thinly covered names where traditional research is limited. I find it valuable for spotting potential shifts that might otherwise go unnoticed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LFVN in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
LFVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where LFVN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LFVN's RSI Indicator exited the oversold zone, 22 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 62 cases where LFVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LFVN as a result. In 83 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for LFVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 46 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for LFVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.957) is normal, around the industry mean (6.914). P/E Ratio (13.050) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.670) is also within normal values, averaging (8.458). Dividend Yield (0.038) settles around the average of (0.049) among similar stocks. P/S Ratio (0.432) is also within normal values, averaging (5.003).
The Tickeron SMR rating for this company is 57 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. LFVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of nutraceutical dietary supplement
Industry FoodMajorDiversified
Advertisement